Skip to main content
Premium Trial:

Request an Annual Quote

Illumina s Revenues Soar, Losses Narrow in Q2

NEW YORK, July 16 (GenomeWeb News) - Illumina reported a steep increase in revenues and smaller losses for the second quarter of 2004 this week.


Revenues for the quarter were $11.5 million, up from $4.8 million during the same period last year.


Research and development costs declined slightly, to $5.3 million, from $6.2 million during the same quarter a year ago.


The company's net loss amounted to $3.5 million, or $.1 per share, down from $8.6 million, or $.27 per share, during the second quarter of 2003.


As of June 27, Illumina had $66.2 million in cash and investments, of which $12.1 million were short term restricted investments.


Tim Kish, the company's CFO, said in a statement that "we remain well positioned to reach breakeven early in 2005."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.